Basel Medical (BMGL) EBITDA Margin (2023 - 2024)
Basel Medical recorded quarterly EBITDA Margin of 11.64% in Q4 2024, down 137.56% quarter-over-quarter from 30.99% in Q4 2023, and down 4263.0% year-over-year from 0.28% in Q1 2024.
Basel Medical's EBITDA Margin history runs 2 years deep, the most recent figure standing at 11.64% for Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | HCA Healthcare | 84.64 Bn | 87.02 Bn | 16.26 Bn | -2.96% |
| 2 | Tenet Healthcare | 15.22 Bn | 14.39 Bn | 4.41 Bn | 24.14% |
| 3 | Davita | 13.10 Bn | 13.96 Bn | 1.07 Bn | 14.11% |
| 4 | Encompass Health | 10.50 Bn | 11.12 Bn | 1.34 Bn | 3.76% |
| 5 | Ensign | 9.69 Bn | 9.09 Bn | 293.37 Mn | 8.99% |
| 6 | Universal Health Services | 8.92 Bn | 8.88 Bn | 3.21 Bn | 11.19% |
| 7 | Fresenius Medical Care AG | 7.31 Bn | 4.93 Bn | 22,843.10 Bn | 0.02% |
| 8 | Chemed | 5.83 Bn | 5.81 Bn | 215.76 Mn | 15.04% |
| 9 | Pacs | 5.76 Bn | 5.51 Bn | 345.96 Mn | 8.45% |
| 10 | Basel Medical | 8.57 Mn | 6.23 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -11.64% |
| Dec 31, 2023 | 30.99% |